novartis generated $40 billion in innovative medicine sales, says ceo
Published 1 year ago • 2.2K plays • Length 3:29Download video MP4
Download video MP3
Similar videos
-
3:04
novartis ceo: spinoffs will see us succeed as a pure-play innovative medicines company
-
4:43
novartis ceo: our leukemia drug scemblix is a potential $3 billion plus medicine
-
11:50
novartis ‘focusing on high-end, innovative medicines,’ ceo says
-
3:29
innovative medicines business returning to growth, novartis ceo says
-
1:14:03
south asian trailblazers: vas narasimhan (ceo of novartis) and srishti gupta (leader in health & ed)
-
32:24
ep. 61 - vas narasimhan: how new data fit novartis’ growth plan
-
1:01:48
why pharmaceuticals are so complicated in the u.s. | cnbc marathon
-
5:53
novartis expects 'strong momentum' going into second half, says ceo vasant narasimhan
-
3:43
novartis ceo vas narasimhan on the latest research on a breast cancer drug
-
0:45
novartis ceo: company set to become a pure play, innovative medicine business after sandoz spin off
-
4:16
novartis ceo vas narasimhan: our medicines are starting to take market share and deliver on promises
-
6:12
novartis ceo: expect continued growth in 2023
-
0:57
novartis global ceo vas narasimhan: ai's impact on pharma and clinical trial realities | n18s
-
0:54
novartis as a focused innovative medicines company
-
5:48
novartis acquires the medicines company for $9.7 billion
-
7:51
watch cnbc's full interview with novartis ceo vas narasimhan
-
0:55
novartis agrees to $6.8 billion medicines co. deal
-
4:37
novartis positioning is now best-suited for long-term gains and returns after spin-off, says ceo
-
6:51
novartis ceo discusses how ai will impact drug development
-
4:54
novartis ceo: confident about continued sales growth for rest of year
-
4:17
novartis ceo: we expect our six key drugs to grow ahead of analyst expectations
-
26:06
looking for a better owner for our india-listed biz: novartis ceo | exclusive | global dialogues